Key result
This narrative review summarizes the pharmacologic features and clinical evidence for adjuvant antithrombotic therapies in patients with STEMI undergoing primary percutaneous coronary intervention.
This narrative review summarizes the pharmacological features and clinical evidence for adjuvant antithrombotic therapies in STEMI patients undergoing primary PCI.
Answers are grounded in this paper and cite their sources.
May guide clinician review of adjuvant antithrombotics in STEMI PCI; leaves open optimal regimens pending new trials.
This article reviews the major pharmacologic features of, and clinical evidence on, adjuvant medical therapy in patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention. These drugs include oral antiplatelets (aspirin and P2Y12 inhibitors such as clopidogrel, prasugrel and ticagrelor), intravenous antiplatelet agents (the P2Y12 inhibitor cangrelor, GP IIb/IIIa inhibitors such as abciximab, eptifibatide and tirofiban), and intravenous anticoagulant agents (unfractionated heparin, low molecular weight heparin and bivalirudin). Neste artigo foram analisadas as principais características farmacológicas e a evidência clínica do uso de terapêutica médica adjuvante em doentes com enfarte do miocárdio com supradesnivelamento do segmento ST tratados com angioplastia primária. Esses fármacos incluem antiagregantes orais (ácido acetilsalicílico e inibidores de P2Y12, tais como clopidogrel, prasugrel, ticagrelor), antiagregantes endovenosos (o inibidor P2Y12 cangrelor, inibidores GpIIbIIIa, como o abciximab, eptifibatide e tirofiban) e agentes anticoagulantes de uso endovenoso (heparina não fracionada, heparina de baixo peso molecular e bivalirudina).
No takes yet. Share an insight, caveat, or question.
Caldeira et al. (2019) conducted a review in ST-elevation myocardial infarction (STEMI). Adjuvant antithrombotic therapy was evaluated. This narrative review summarizes the pharmacologic features and clinical evidence for adjuvant antithrombotic therapies in patients with STEMI undergoing primary percutaneous coronary intervention.
Synapse has enriched 10 related papers. Consider them for comparative context: